Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies

Gilead Sciences, Inc. (NASDAQ:GILD) and Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Wednesday entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2), with broad oncology treatment potential.

CDK2-directed MGDs are a new type of drug designed to remove CDK2, a key contributor to tumor growth, rather than just inhibiting its function.

Kymera can receive up to $750 million in total payments, including up to $85 million in upfront and potential option exercise payments.

Also Read: Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron’s Blockbuster Dupixent In Early Biomarker Response

In addition, Kymera may receive tiered royalties ranging from the high single-digits to the mid-teens on net product sales under the collaboration. Kymera will lead all research activities for the CDK2 program.

If Gilead exercises its option to exclusively license the program, Gilead will have ...